Top 20 Pharma Ranks: As Some Move Up, Others Fall Down
Sanofi and Gilead moved down in the rankings of Scrip's top 100 pharmaceutical companies, based on 2017 pharma sales, while Johnson & Johnson, GSK and AbbVie moved up. Shire joined the top 20 just as it is about to be consumed by Takeda.
You may also be interested in...
FDA’s approval teams cleared a total of 65 new molecular entities and novel biologics in 2018, blowing past previous records. Scrip looks at how that breaks down for industry leaders.
Allying itself with US biotech Agenus underscores Gilead's oncology ambitions, which incoming CEO-designate Daniel O'Day must make good on.
Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.